CHENGDU, China, July 22, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the research, development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that the Company has shipped the first batch of Azithromycin API sample to RELATIONS International Ltd. for Bangladesh export standard test.
This is the first step for the development of macrolide international export business for TPI following the signing of the sales and marketing agreement with RELATIONS International Ltd., a Bangladesh corporation that specializes in API product sales in the People's Republic of Bangladesh, in June this year.
Jiangchuan Macrolide facility (JCM) currently has an active production license for manufacturing Azithromycin API (H10970072). Additional information regarding JCM can be found at www.sfda.gov.cn (Chinese version).
Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.
For more information about TPI, please visit: http://www.tianyinpharma.com